Celsis International has acquired In Vitro Technologies, Inc. for $30 million in cash and an earn-out consideration capped at $5 million. The acquisition of IVT adds a suite of products and services for the in vitro ADME toxicology market to the Celsis portfolio. Based in Baltimore, MD, IVT supplies products and services to improve the drug discovery and development process. IVT’s product portfolio includes proprietary ADME-Tox products including fresh and cyropreserved cells and enzy...